ASH 2023 | Thrombomodulin protects against acute kidney injury in sickle cell mice
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, discusses the protective nature of thrombomodulin, which was determined in a study of transgenic mice with sickle cell. Thrombomodulin protects against cell-free hemoglobin mediated acute kidney injury (and possibly lung injury) due to its anti-thrombotic characteristics and complement inhibition. Dr Saraf hopes that this research will have clinical implications for patients with sickle cell disease (SCD), as it highlights thrombomodulin as a candidate for preserving vascular function and avoiding the multi-organ damage which can occur in patients during severe vaso-occlusive or hyperhemolytic episodes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Advisory board: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Research Funding: Novartis, Forma Therapeutics, GBT/Pfizer
Speakers Bureau: GBT/Pfizer
